SPARC seeks US FDA nod to start phase 1 trial of SBO-154 to treat advanced solid tumours: Our Bureau, Mumbai Monday, March 31, 2025, 12:15 Hrs [IST] Sun Pharma Advanced Research C ...

Sun Pharma Advanced Research Company (SPARC) said that it has submitted an investigational new drug (IND) application with the US Food and Drug Administration (FDA) for its antibody-drug conjugate ...

a bispecific ADC that targets MUC1 and EGFR, is in phase 1/1b trials for non-small-cell lung cancer and esophageal cancer. Additional drug candidates enabled by Sutro’s platform currently in ...

“MUC1 is over-expressed in multiple solid tumors ... an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. PDS Biotechnology NewsMORE Related Stocks ...

TA-MUC1, the target of gatipotuzumab ... Since 2023, ADCs have dominated high-value pharmaceutical deals. The global ADC market is expected to grow as currently approved and pipeline ADCs become ...

Mumbai: Sun Pharma Advanced Research Company Ltd. has announced submission of an Investigational New Drug (IND) application ...

“SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.” said Anil ...

“MUC1 is over-expressed in multiple solid tumors including colon, pancreatic, ovarian, breast, and NSCLC, and is associated with drug resistance and poor patient outcomes. This results in an ...

SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally. said Anil Raghavan ...